期刊文献+

卡铂联合力尔凡治疗恶性胸腔积液的临床研究 被引量:1

Clinical study of carboplatin in combined with lifein for malignant pleural effusions
下载PDF
导出
摘要 目的 :恶性胸腔积液是恶性肿瘤患者晚期常见的并发症 ,单纯抽液容易复发 ,胸腔内注入抗癌药物是提高疗效的有效方法。卡铂和力尔凡均为治疗恶性积液的有效药物 ,我们应用这两种药物 ,以评价其治疗恶性胸腔积液的疗效和毒性。方法 :6 0例恶性胸腔积液随机分为两组 ,A组单用卡铂 ,B组卡铂与力尔凡联合应用。结果 :在治疗的第一个月 ,A组CR率 81%,B组CR率 88%;3个月后A组CR率为 6 5 %,B组CR率为 99%,两组差异均无显著性 (P >0 .0 5 ) ;6个月后CR率 ,A组为4 0 %,B组为 6 0 %,两组差异有显著性 (P <0 .0 5 )。 6个月生存率两均为 10 0 %(P >0 .0 5 ) ,12个月后CR率A组为 15 %,B组为 35 .6 %(P <0 .0 5 ) ;18个月生存率A组为 0 ,B组为 16 .4 %(P <0 .0 5 )。两组不良反应主要有低热、胸痛、胃肠道反应 ,经对症处理可缓解。结论 :卡铂联合力尔凡治疗恶性胸腔积液的疗效明显高于单药卡铂。 Objective: Malignant pleural is a common complication for cases of late stage malignant tumor, with single draining of the pleural cavity by theoracocentesis, the cases mostly have a relapse. Medicine against cancer administered into intracavity in an effective method to improve the curative effective medicine for the treatment of malignant pleural effusion. They were combined to be administered in order to evaluate their effects and toxi cities. Methods: Sixty patients with malignant pleural effusion were randomized into administered; In group A, only corboplatin was administered; In group B, Lifein and carboplatin were combined together to be administered. Result: In the first month posteriorly to treatment, the rate of Cr was 81% in group A, 88% in group B, After three moths 65% in group A, 99% in group B ((P>0.05). After 6-months the rate of CR was 40% in group A, 60% in group B (P<0.05). The 6-month survival rate were both 100% in group A and in group B (P>0.05). After 12 month, Cr rate was 15% in group A, 35.6% group B (P<0.05). The 18-month survival rate were 0% in group A, 16.4%in group B .The main adverse reactions were gastroentevic tract reaction, thoracodynin, and low fever which could be controlled. Conclusion: The curative effect of carboplatin combined with Lifein in the treatment of malignant pleural effusion is apparently superior to that of single carboplatin.
作者 刘怀深
出处 《河北医学》 CAS 2003年第9期792-793,共2页 Hebei Medicine
关键词 胸腔积液 卡铂 力尔凡 Malignant pleural effusion Carboplatin Lifein
  • 相关文献

参考文献5

二级参考文献20

  • 1廖美淋.恶性胸腔积液的处理[J].实用内科杂志,1989,9(1):10-11. 被引量:38
  • 2潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 3王长利 邢勇 等.胸腔闭式引流胸内注入卡多功能铂治疗恶性胸腔液[J].中国肿瘤临床,1998,25(9):633-633.
  • 4王舒宝.欧耐特三期临床观察总结.重组人白细胞介素-2论文集[M].,1998,1.2.
  • 5李田 缭劲.白细胞介素-2治疗肺癌癌性胸水[J].南京医科大学学报,1995,15:215-215.
  • 6宋鹏 段蕴铀 等.欧耐特胸腔红药治疗生胸腔积液.重组人白细胞介素-Ⅱ论文集[M].,1998,1.2.
  • 7俞森洋 蔡柏蔷.呼吸内科主治医师410问[M].北京:北京医科大学、中国协和医科大学联合出版社,1997.525.
  • 8宋鹏,重组人白细胞介素-Ⅱ论文集,1998年,1期,2页
  • 9王舒宝,重组人白细胞介素-Ⅱ论文集,1998年,1期,2页
  • 10张天泽,肿瘤学.下,1996年,2590,2666页

共引文献68

同被引文献22

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部